triptorelin / Generic mfg. - LARVOL DELTA

Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls. (PubMed, Endocr Connect) - "This study tested triptorelin stimulation as an alternative to the standard gonadorelin test to diagnose precocious puberty in girls. Triptorelin proved equally accurate and reliable, especially when hormone levels are measured 3 h after injection, offering a practical diagnostic tool in clinical practice."

Journal • Endocrine Disorders

Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study (ESMO Asia 2025) - P3 | "The triptorelin 6-month formulation demonstrates high effectiveness for achieving and maintaining castration in Chinese patients with advanced PC, with a safety profile consistent with global studies and no new tolerability concerns."

Clinical • Metastases • P3 data • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Results of repeat core needle biopsies in ER+/HER2-negative breast cancer following neoadjuvant endocrine therapy with fulvestrant+triptorelin+ribociclib in premenopausal women (ESMO Asia 2025) - "The fulvestrant+triptorelin+ribociclib combination (NET) induced rapid reduction in proliferative activity (Ki-67), modulation of hormone receptor expression. Observed changes may reflect the tumor heterogeneity or pharmacodynamic treatment effects. The clinical significance of marker dynamics requires long-term follow-up to assess prognostic value."

Biopsy • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2027 ➔ Nov 2028 | Trial primary completion date: Jan 2027 ➔ Nov 2028

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=112 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Elacestrant alone or in combination with triptorelin in premenopausal women with ER+/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- PremiÈRe trial (SABCS 2025) - P2 | "Ovarian function suppression (OFS) in combination with tamoxifen or aromatase inhibitors improves disease-free survival but has limitations such as toxicity, suboptimal estrogen suppression, and poor adherence. This study provides the first evidence that ELA ± OFS elicits antiproliferative and molecular responses in premenopausal women with ER+/HER2- EBC. Both regimens had comparable and significant reductions in Ki67, CCCA, ROR-P scores, and proliferation gene expression. PremiÈRe trial support the potential role of ELA as a novel ET in this population, potentially sparing the need for OFS."

Clinical • Combination therapy • P2 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Sustained Ovarian Function Suppression with Triptorelin in Premenopausal HR+ HER2− Breast Cancer: Results from the Second Interim Analysis of the ROSE Study (SABCS 2025) - P | "Patients received adjuvant endocrine therapy (tamoxifen or aromatase inhibitors [AI]) plus triptorelin (1- or 3-month formulation), started either concurrently or sequentially with chemotherapy...Among patients (9.7%) receiving triptorelin + AI + abemaciclib, hormonal suppression seemed comparable to that observed in other AI-based combinations (71.8%)... In this second interim analysis of the ROSE study, triptorelin was shown to effectively and durably suppress ovarian function over time in premenopausal women with HR+ HER2− EBC, across multiple treatment settings. These findings support the role of long-term hormonal monitoring and reinforce the use of OFS as a key component of endocrine-based strategies in this population. Final analyses from the full cohort will help refine patient selection and personalization of OFS regimens."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A retrospective analysis of spontaneous reports of suspected adverse drug reactions to triptorelin acetate in a tertiary pediatric medical center: still a lot of preventable harm. (PubMed, BMC Pediatr) - "The majority of ADRs observed in pediatric cases were type I anaphylactic reactions, which are rare but life-threatening. It is advisable to perform skin prick tests and intradermal tests when switching pharmaceutical manufacturers."

Adverse drug reaction • Journal • Retrospective data • Endocrine Disorders • Musculoskeletal Pain • Pediatrics

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) (clinicaltrials.gov) - P3 | N=56 | Active, not recruiting | Sponsor: Debiopharm International SA | Recruiting ➔ Active, not recruiting

Enrollment closed • Endocrine Disorders • Pediatrics

COMPASS - COpenhagen MenoPAuSe Study (clinicaltrials.gov) - P2 | N=192 | Recruiting | Sponsor: Martin Blomberg Jensen

New P2 trial • Osteoporosis • Rheumatology

The Diagnostic Utility of the Triptorelin Stimulation Test Compared to the Standard Gonadotropin-Releasing Hormone Stimulation Test in Children with Idiopathic Central Precocious Puberty. (PubMed, Diseases) - "Both GnRH and triptorelin stimulation tests are valid tools for CPP diagnosis. However, the GnRH test appears to elicit a more robust LH response, especially in younger patients, whereas the triptorelin test is associated with delayed and lower LH peaks."

Journal • Endocrine Disorders • Pediatrics • IGF1

Watchful waiting in prostate cancer: Analysis of predictive factors for treatment necessity (EMUC 2025) - "Among patients with metastatic progression, all received androgen deprivation therapy (ADT): four underwent bilateral orchiectomy, two were treated with LHRH agonists (triptorelin) plus a first-generation antiandrogen (bicalutamide), and one received LHRH agonist plus apalutamide. Among the non-metastatic patients who initiated treatment, five underwent orchiectomy, three received LHRH agonists either alone or with bicalutamide, and three were treated with radiotherapy in combination with ADT—one of whom also received abiraterone...Subsequent treatment included enzalutamide in three cases and darolutamide in one...Conclusions In this cohort, WW was safe, with low treatment and progression rates. Histological factors, namely ISUP grade and number of positive cores, were predictive of treatment need, reinforcing their role in initial risk stratification."

Biomarker • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

SEQ: Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial (clinicaltrials.gov) - P4 | N=62 | Not yet recruiting | Sponsor: Fundacion Dexeus

New P4 trial • Genetic Disorders • Gynecology • Infertility • Obesity • Sexual Disorders

Triptorelin: The Need for Legal Protection Aimed at the Full Political and Social Integration of Gender Variant youth. A Comparison of Different Global realities. (PubMed, Clin Ter) - "The article calls for a more inclusive and multidisciplinary healthcare system in Italy, emphasizing the need for clear guidelines, better training for healthcare professionals, and increased access to gender-affirming care. Despite progress, political and social barriers persist, highlighting the need for structural reforms to ensure the rights and well-being of transgender youth."

Clinical • Journal • Review • CNS Disorders

Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer. (PubMed, JAMA Netw Open) - "Luteinizing hormone-releasing hormone agonists (leuprolide, goserelin, or triptorelin) use as a time-dependent variable and first-line systemic therapy. Although excess risks differed slightly between Black and White patients, overall differences were small. These findings highlight the need for monitoring and mitigation strategies for patients receiving ADT."

Adverse events • Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Genito-urinary Cancer • Heart Failure • Musculoskeletal Diseases • Myocardial Infarction • Oncology • Peripheral Arterial Disease • Prostate Cancer • Rheumatology • Solid Tumor

Tales from the clinic: A case of congenital long QT syndrome and medically induced menopause. (PubMed, Post Reprod Health) - "This is a case report of a 47-year-old woman with known Long QT Syndrome who was given GnRH analogues to induce menopause prior to hysterectomy for fibroids who suffered several episodes of ventricular fibrillation leading to Torsades de Pointes cardiac arrests. This paper discusses the case and the physiological backdrop of hormone influences on the QT interval in women, includes the patient perspective and makes recommendations."

Journal • Cardiovascular • Gynecology • Uterine Leiomyoma

Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis (ISPOR-EU 2025) - "Linzagolix was compared against a composite of injectable GnRH agonists (leuprorelin acetate, goserelin, triptorelin). Linzagolix+ABT is cost-effective, enhances HRQoL, and reduces the need for radical surgeries, thereby also helping to preserve fertility. These benefits strongly support the adoption of linzagolix into clinical practice for endometriosis management."

HEOR • Endometriosis • Gynecology • Musculoskeletal Pain • Osteoporosis • Rheumatology • Women's Health

Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys? (PubMed, Ann Pediatr Endocrinol Metab) - No abstract available

Journal • Endocrine Disorders

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: OHSU Knight Cancer Institute | N=32 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • IO biomarker • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • PD-L1

Epidemiology of Gender-Affirming Hormone Treatment From Multistate Administrative Data (AACAP 2025) - "We computed the demographic data and co-prescription of psychotropic medications (SSRIs, antipsychotics, etc) in 3 nonmutually exclusive groups (estrogen [E], testosterone [T], and puberty blockers [PB]). After their first GD diagnosis, 3.3% to 22.3% of adolescents and 17.8% to 45.8% of young adults received GAHT (T, estradiol, and spironolactone), and 4.5% to 13.3% of adolescents and <3% of young adults received the most commonly used pubertal suppression treatments (leuprolide and triptorelin) in the following 2 years. GAHT and PB are common among adolescents and young adults with gender dysphoria within 2 years of diagnosis. The demographic profile revealed predominantly male and/or White individuals. Psychotropic medications were commonly co-prescribed across all groups."

Clinical • CNS Disorders

Efficacy of Huayu Xiaozheng decoction combined with triptorelin and mifepristone in the treatment of uterine fibroids and its effect on uterine artery hemodynamics. (PubMed, Int J Gynaecol Obstet) - "HYXZD combined with triptorelin and mifepristone improves clinical outcomes in uterine fibroid treatment by reducing fibroid size, optimizing hormone levels and hemodynamics, lowering tumor markers, and maintaining safety."

Journal • Gynecology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health

The value of urinary gonadotropin after triptorelin stimulation tests for diagnosing central precocious puberty in girls with overweight or obesity: a single-center study. (PubMed, BMC Pediatr) - "For overweight or obese girls with precocious puberty, the first stimulated ULH/Cr (cut-off value 240 IU/mol) may be used as a possible alternative to the invasive blood detection of triptorelin stimulation tests for diagnosing CPP."

Journal • Retrospective data • Endocrine Disorders • Genetic Disorders • Obesity • Pediatrics

Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study. (PubMed, Ther Adv Urol) - P=N/A | "In France, compliance with continuous triptorelin treatment for 12 months is high and prescribing aligns with guideline recommendations. NCT04593420."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - P3 | N=1538 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed

Trial completion • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor